AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS

Claims 1-65 (cancelled)

66. (currently amended) A compound of the formula



or a pharmaceutically acceptable salt thereof, wherein

is a 4-8 membered monocyclic ring or 7-12 membered bicyclic ring; which ring is optionally saturated or unsaturated, which ring is optionally substituted with one or more substituent selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, thioalkyl, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and -$(CH_2)_m$ COR;

m is 0 to 2;

R is hydroxy, alkoxy, alkyl or amino;

A^1 is a pyridinyl of the formula



optionally substituted by one or more R^k selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide and -COR;

R is hydroxy, alkoxy, alkyl or amino;

with respect to Z^1 and Z^2:

Z^1 is selected from the group consisting of CH_2, O, N, CO, S, SO, SO_2,  and NR_k;

R_k is selected from H or lower alkyl;

Z^2 is a 2 to 5 carbon linker optionally containing one or more heteroatom selected from the group consisting of O, S and N; or

Z^1 - Z^2 contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenylene, alkynylene, and acyl;

wherein the carbon and nitrogen atoms of Z^1 - Z^2 are optionally substituted by alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl or acylamino;

wherein Z_2 - Z_1 is attached to 

at the para or meta position relative to the X_1 substituent;

n is 0 to 2;

R^c is selected from the group consisting of hydrogen; alkyl; halogen, hydroxy, nitro, alkoxy, amino, haloalkyl, aryl, heteroaryl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, thioalkyl, alkylamino, arylamino, alkylsulfonylamino, acyl, acylamino, sulfonyl, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, alkynylalkyl, carboxy, alkoxycarbonyl, carboxamido, cyano, and $-(CH_2)_m$ COR;

X^1 is selected from the group consisting of -O-, CO, SO_2, NR^m and $(CHR^p)_q$;

R^m is H or alkyl;

R^p is H, alkyl; alkoxy or hydroxy;

q is 0 or 1;

with respect to X, X^2 and Y:

X^2 is selected from the group consisting of $-CHR^e-$, CO, SO_2, O, NR^f and S;

R^f is H or alkyl;

R^e is selected from the group consisting of H, alkyl, hydroxy and alkoxy;

X or Y are independently selected from the group consisting of $-CR^g-$ or -N- wherein R^g is selected from the group consisting of H, alkyl, haloalkyl, fluoro, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkylsulfone, hydroxyalkyl, hydroxy, alkoxy, and carboxyalkyl; or

the group $X-X_2-Y$ contains a moiety selected from the group consisting of acyl, alkyl, amino, ether, thioether, sulfone and olefin;



forms a cycloalkyl, optionally substituted with one or more substituent selected from the group consisting of alkyl, halogen, cyano, carboalkoxy, haloalkyl, alkoxyalkyl, alkylsulfone, aryl, heteroaryl, ~~arakyl, heteroarakyl,~~ aralkyl, heteroaralkyl, or alkoxy; and

R^b is X_3 - R^h wherein X_3 is selected from the group consisting of O, S and NR^j wherein R^h and R^j are independently selected from the group consisting of H, alkyl, acyl, aryl, aralkyl and alkoxyalkyl.

67. (previously presented) A compound according to claim 66 wherein

A^1 is selected from the group consisting of



;

Z^a is selected from the group consisting of H, alkyl, alkoxy, hydroxy, amine, alkylamine, dialkylamine, carboxyl, alkoxycarbonyl, hydroxyalkyl, halogen and haloalkyl; and

R^1 is selected from the group consisting of H, alkyl, alkoxyalkyl, acyl, haloalkyl, alkoxycarbonyl, pyridylamino, imidazolylamino, morpholinopyridine, tetrahydronaphthyridine, oxazolylamino, thiazolylamino, pyrimidinylamino, quinoline, isoquinoline, tetrahydroquinoline, imidazopyridine, benzimidazole, pyridone, and quinolone.

68. (currently amended) A compound according to claim 66 wherein

A^1 is selected from the group consisting of  ;

X^4 is selected from the group consisting of H, alkyl, branched alkyl, alkylamino, ~~aloxyalkylamino,~~ alkoxyalkylamino, haloalkyl, thioalkyl, halogen, amino, alkoxy, aryloxy, alkoxyalkyl, hydroxy, cyano and acylamino;

X^5 is selected from the group consisting of H, alkyl, branched alkyl, alkylamino, ~~aloxyalkylamino,~~ alkoxyalkylamino, haloalkyl, thioalkyl, halogen, amino, alkoxy, aryloxy, alkoxyalkyl, hydroxy, cyano and acylamino;

X^6 is selected from the group consisting of H, alkyl, halogen, alkoxy, hydroxy, and haloalkyl; and

R^{79} is selected from the group consisting of hydroxy, alkoxy, alkyl and amino.

69. (currently amended) A compound according to the claim 66 wherein

the moiety A^1-Z^2 is selected from the group consisting of

 ;

X^4 is selected from the group consisting of H, alkyl, branched alkyl, alkylamino, ~~aloxyalkylamino,~~ alkoxyalkylamino, haloalkyl, thioalkyl, halogen, amino, alkoxy, aryloxy, alkoxyalkyl, hydroxy, cyano and acylamino;

R^{80} is selected from the group consisting of hydroxy, alkoxy, alkyl and amino;

R^{81} is selected from the group consisting of hydroxy, alkoxy, alkyl and amino; and

R^{82} is selected from the group consisting of hydroxy, alkoxy, alkyl and amino.

70. (previously presented) A compound according to claim 66 wherein

X_1 is $(CHR^p)_q$; wherein q = 0;

B is a 3-, 4-, or a 5-membered cycloalkyl obtained by combining X-X_2-Y;

A is a phenyl ring substituted with R^c; and

n = 1.

71. (previously presented) A compound according to claim 70,



wherein the ring B is a cyclopropyl;

Y = CR^g;

wherein R^g is selected from the group consisting of H, alkyl, haloalkyl, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkylsulfone, hydroxyalkyl, hydroxy, alkoxy, and carboxyalkyl;

A is a phenyl ring substituted with R^c; and

R^b = OH.

72. (currently amended) A compound according to claim 71 wherein R^g is selected from the group consisting of





R^{83} is selected from the group consisting of H, alkyl, OMe, OH, and halogen;

X^7 is selected from the group consisting of CH2 and O;

R^{84} is selected from the group consisting of H, alkyl, OMe, OH, and halogen;

R^{85} is selected from the group consisting of H, alkyl, OMe, OH, and halogen;

X^8 is selected from the group consisting of NH, NMe, O, and S;

R^{86} is selected from the group consisting of H and Me;

R^{87} is selected from the group consisting of H and Me;

R^{88} is selected from the group consisting of H, alkyl, OMe, OH, and halogen;

R^{89} is selected from the group consisting of H and Me;

B^1 is selected from the group consisting of O, SO2, S and CO;

R^{90} is selected from the group consisting of alkyl and aryl;

R^{91} is selected from the group consisting of alkyl and aryl; and

R^{92} is selected from the group consisting of aryl and ~~heteroayl~~ heteroaryl.

73. (previously presented) A compound according to claim 71 wherein

A^1 is selected from the group consisting of



;

X^9 is selected from the group consisting of H, alkyl, and acyl;

R^{93} is selected from the group consisting of H, Me, OH and alkoxyalkyl; and

R^{93} is selected from the group consisting of H, Me, OMe, and OH.

74. (previously presented) A compound according to claim 71 wherein

ring A is a phenyl ring; and

Z_1-Z_2 and X_1-X are connected para to each other.

75. (previously presented) A compound according to claim 74 wherein the phenyl ring is optionally substituted with one or more substituents selected from the group consisting of alkyl; halogen, hydroxy, alkoxy, haloalkyl, aryl, heteroaryl, alkoxyalkyl, sulfonamide, methylenedioxy, ethylenedioxy, alkynyl, and alkynylalkyl.

76. (previously presented) A compound according to claim 74 wherein Z_1 is selected from the group consisting of CH_2, O, NR_k, CO, S, SO, and SO_2.

77. (previously presented) A compound according to claim 74 wherein A^1 is selected from the group consisting of



78. (previously presented) A compound according to the claim 66,



wherein

X^1 is $(CHR^p)_q$; wherein q = o;

A is a phenyl ring substituted with R^c

B is a cyclopropyl obtained by combining $X\text{-}X_2\text{-}Y$;

n = 1; and

R_m and R_n are selected from the group consisting of H, alkyl, halogen, alkoxy, haloalkyl, alkoxyalkyl, alkylsulfone, cyano, carboalkoxy, aryl, heteroaryl, aralkyl and heteroaralkyl; or

R_m and R_n form a spirocyclic ring system.

79. (previously presented) A compound according to the claim 78 wherein A^1 is selected from the group consisting of



;

R^{94} is selected from the group consisting of H, Me, OH, and alkoxyalkyl;

R^{94} is selected from the group consisting of H, Me, OMe, and OH; and

X^9 is selected from the group consisting of H, alkyl, and acyl.

80. (previously presented) A compound according to claim 66 selected from the group consisting of:
2-[4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropaneacetic acid;
2-[4-[3-(2-pyridinylamino)propoxy]phenyl] cyclopentaneacetic acid;
3-[4-[3-(2-pyridinylamino)propoxy]phenyl] cyclopentaneacetic acid;
2,2-difluoro-3-[4-[3(2-pyridinylamino)propoxy]phenyl]cyclopropane-acetic acid
(2-{4-[2-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid;
2-[3-methyl-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropane-acetic acid;
2-[2-methoxy-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropane-acetic acid;
2-[2-methyl-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropane-acetic acid;
2-[3-fluoro-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropaneacetic acid;
2-[2-fluoro-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropaneacetic acid;
2-[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]cyclopropane-acetic acid;
2-[4-[2-(3,4-dihydro-2*H*-pyrido[3,2-*b*]-1,4-oxazin-6-yl)ethoxy]phenyl]-cyclopropaneacetic acid;
3-[4-[3-(2-pyridinylamino)propoxy]phenyl]cyclobutaneacetic acid;
(2-{2-Methoxy-4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;
(2-{2-Fluoro-4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;
(2-{2-Acetoxy-4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;
(1-Methyl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;
(1-Methoxymethyl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;
(1-Methanesulfonylmethyl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;
(1-Pyridin-3-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;
(1-Benzo[1,3]dioxole-5-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-(2,3-Dihydro-benzofuran-6-yl)-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-Isoxazol-3-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-Isoxazol-5-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-Oxazol-5-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(2-{4-[3-(Pyridin-2-ylamino)-propoxy]-phenyl}-1-thiazol-5-yl-cyclopropyl)-acetic acid;

(1-Pyridin-3-yl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-Methyl-2-{4-[2-(6-methylamino-pyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid;

(2-{4-[2-(6-Ethylamino-pyridin-2-yl)-ethoxy]-phenyl}-1-methyl-cyclopropyl)-acetic acid;

[2-(4-{2-[6-(2-Methoxy-ethylamino)-pyridin-2-yl]-ethoxy}-phenyl)-1-methyl-cyclopropyl]-acetic acid;

[2-(4-{2-[6-(3-Methoxy-propylamino)-pyridin-2-yl]-ethoxy}-phenyl)-1-methyl-cyclopropyl]-acetic acid;

(2-{4-[2-(6-Acetylamino-pyridin-2-yl)-ethoxy]-phenyl}-1-methyl-cyclopropyl)-acetic acid;

[1-Methyl-2-(4-{2-[6-(2,2,2-trifluoro-ethylamino)-pyridin-2-yl]-ethoxy}-phenyl)-cyclopropyl]-acetic acid;

(2-{4-[2-(6-Ethylamino-pyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

[2-(4-{2-[6-(2-Methoxy-ethylamino)-pyridin-2-yl]-ethoxy}-phenyl)-cyclopropyl]-acetic acid;

[2-(4-{2-[6-(2,2,2-Trifluoro-ethylamino)-pyridin-2-yl]-ethoxy}-phenyl)-cyclopropyl]-acetic acid;

[2-(4-{2-[6-(3-Methoxy-propylamino)-pyridin-2-yl]-ethoxy}-phenyl)-cyclopropyl]-acetic acid; and

(2-{4-[2-(6-Acetylamino-pyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid.

81. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 66 and a pharmaceutically acceptable carrier.

82. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 70 and a pharmaceutically acceptable carrier.

83. (previously presented) A method for treating conditions mediated by the $\alpha_V\beta_3$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_V\beta_3$ inhibiting amount of a compound of Claim 66.

84. (currently amended) A method for treating conditions mediated by the $\alpha_V\beta_3$ integrin in a mammal in need of such treatment ~~compirisng~~ comprising administering an effective $\alpha_V\beta_3$ inhibiting amount of a compound of Claim 70.

85. (previously presented) The method according to Claim 83 wherein the condition treated is tumor metastasis.

86. (previously presented) The method according to Claim 84 wherein the condition treated is tumor metastasis.

87. (previously presented) The method according to Claim 83 wherein the condition treated is solid tumor growth.

88. (previously presented) The method according to Claim 84 wherein the condition treated is solid tumor growth.

89. (previously presented) The method according to Claim 83 wherein the condition treated is angiogenesis.

90. (previously presented) The method according to Claim 84 wherein the condition treated is angiogenesis.

91. (previously presented) The method according to Claim 83 wherein the condition treated is osteoporosis.

92. (previously presented) The method according to Claim 84 wherein the condition treated is osteoporosis.

93. (previously presented) The method according to Claim 83 wherein the condition treated is humoral hypercalcemia of malignancy.

94. (previously presented) The method according to Claim 84 wherein the condition treated is humoral hypercalcemia of malignancy.

95. (previously presented) The method according to Claim 83 wherein the condition treated is smooth muscle cell migration.

96. (previously presented) The method according to Claim 84 wherein the condition treated is smooth muscle cell migration.

97. (previously presented) The method according to Claim 83 wherein restenosis is inhibited.

98. (previously presented) The method according to Claim 84 wherein restenosis is inhibited.

99. (previously presented) The method according to Claim 83 wherein atheroscelorosis is inhibited.

100. (previously presented) The method according to Claim 84 wherein atheroscelorosis is inhibited.

101. (previously presented) The method according to Claim 83 wherein macular degeneration is inhibited.

102. (previously presented) The method according to Claim 84 wherein macular degeneration is inhibited.

103. (previously presented) The method according to Claim 83 wherein retinopathy is inhibited.

104. (previously presented) The method according to Claim 84 wherein retinopathy is inhibited.

105. (previously presented) The method according to Claim 83 wherein arthritis is inhibited.

106. (previously presented) The method according to Claim 84 wherein arthritis is inhibited.

107. (previously presented) A method for treating conditions mediated by the $\alpha_v\beta_5$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_5$ inhibiting amount of a compound of Claim 66.

108. (previously presented) A method for treating conditions mediated by the $\alpha_v\beta_5$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_5$ integrin inhibiting amount of a compound of Claim 70.

109. (previously presented) The method according to Claim 107 wherein the condition treated is $\alpha_V\beta_5$ integrin mediated-tumor metastasis.

110. (previously presented) The method according to Claim 108 wherein the condition treated is $\alpha_V\beta_5$ integrin mediated-tumor metastasis.

111. (previously presented) The method according to Claim 107 wherein the condition treated is $\alpha_V\beta_5$ integrin mediated-solid tumor growth.

112. (previously presented) The method according to Claim 108 wherein the condition treated is $\alpha_V\beta_5$ integrin mediated-solid tumor growth.

113. (previously presented) The method according to Claim 107 wherein the condition treated is angiogenesis.

114. (previously presented) The method according to Claim 108 wherein the condition treated is angiogenesis.

115. (previously presented) The method according to Claim 107 wherein the condition treated is osteoporosis.

116. (previously presented) The method according to Claim 108 wherein the condition treated is osteoporosis.

117. (previously presented) The method according to Claim 107 wherein the condition treated is humoral hypercalcemia of malignancy.

118. (previously presented) The method according to Claim 108 wherein the condition treated is humoral hypercalcemia of malignancy.

119. (previously presented) The method according to Claim 107 wherein the condition treated is smooth muscle cell migration.

120. (previously presented) The method according to Claim 108 wherein the condition treated is smooth muscle cell migration.

121. (previously presented) The method according to Claim 107 wherein restenosis is inhibited.

122. (previously presented) The method according to Claim 108 wherein restenosis is inhibited.

123. (previously presented) The method according to Claim 107 wherein atherosclerosis is inhibited.

124. (previously presented) The method according to Claim 108 wherein atherosclerosis is inhibited.

125. (previously presented) The method according to Claim 107 wherein macular degeneration is inhibited.

126. (previously presented) The method according to Claim 108 wherein macular degeneration is inhibited.

127. (previously presented) The method according to Claim 107 wherein retinopathy is inhibited.

128. (previously presented) The method according to Claim 108 wherein retinopathy is inhibited.

129. (previously presented) The method according to Claim 107 wherein arthritis is inhibited.

130. (previously presented) The method according to Claim 108 wherein arthritis is inhibited.